Correlation Between CHINA DEVELOPMENT and Foresee Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both CHINA DEVELOPMENT and Foresee Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CHINA DEVELOPMENT and Foresee Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between CHINA DEVELOPMENT FINANCIAL and Foresee Pharmaceuticals Co, you can compare the effects of market volatilities on CHINA DEVELOPMENT and Foresee Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CHINA DEVELOPMENT with a short position of Foresee Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of CHINA DEVELOPMENT and Foresee Pharmaceuticals.

Diversification Opportunities for CHINA DEVELOPMENT and Foresee Pharmaceuticals

-0.69
  Correlation Coefficient

Excellent diversification

The 3 months correlation between CHINA and Foresee is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding CHINA DEVELOPMENT FINANCIAL and Foresee Pharmaceuticals Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Foresee Pharmaceuticals and CHINA DEVELOPMENT is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CHINA DEVELOPMENT FINANCIAL are associated (or correlated) with Foresee Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Foresee Pharmaceuticals has no effect on the direction of CHINA DEVELOPMENT i.e., CHINA DEVELOPMENT and Foresee Pharmaceuticals go up and down completely randomly.

Pair Corralation between CHINA DEVELOPMENT and Foresee Pharmaceuticals

Assuming the 90 days trading horizon CHINA DEVELOPMENT FINANCIAL is expected to generate 0.17 times more return on investment than Foresee Pharmaceuticals. However, CHINA DEVELOPMENT FINANCIAL is 5.99 times less risky than Foresee Pharmaceuticals. It trades about 0.17 of its potential returns per unit of risk. Foresee Pharmaceuticals Co is currently generating about -0.14 per unit of risk. If you would invest  779.00  in CHINA DEVELOPMENT FINANCIAL on September 27, 2024 and sell it today you would earn a total of  6.00  from holding CHINA DEVELOPMENT FINANCIAL or generate 0.77% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy95.65%
ValuesDaily Returns

CHINA DEVELOPMENT FINANCIAL  vs.  Foresee Pharmaceuticals Co

 Performance 
       Timeline  
CHINA DEVELOPMENT 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in CHINA DEVELOPMENT FINANCIAL are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, CHINA DEVELOPMENT is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.
Foresee Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Foresee Pharmaceuticals Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

CHINA DEVELOPMENT and Foresee Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with CHINA DEVELOPMENT and Foresee Pharmaceuticals

The main advantage of trading using opposite CHINA DEVELOPMENT and Foresee Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CHINA DEVELOPMENT position performs unexpectedly, Foresee Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Foresee Pharmaceuticals will offset losses from the drop in Foresee Pharmaceuticals' long position.
The idea behind CHINA DEVELOPMENT FINANCIAL and Foresee Pharmaceuticals Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories